Amneal Pharmaceuticals Inc. Class A (AMRX)
NASDAQ: AMRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 9:59 AM ET
AMRX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $6.74B
- P/E (TTM)
- 39.48
- Forward P/E
- 16.22
- EPS (TTM)
- $0.49
- Dividend yield
- None
- 52-week range
- 9.56 – 21.18
- Day range
- 19.25 – 19.65
- Volume / Avg
- 200.99K / 2.26M
- Beta
- —
- Shares outstanding
- 348.30M
- Next earnings
- Oct 29, 2026
52-week range
AMRX stock today
Amneal Pharmaceuticals (AMRX) is trading at $19.35 on Oct 8, down 1.55% (-$0.305), versus the S&P 500's 0.28% decline. At this level, AMRX sits near the top of its 52-week range of $9.56 to $21.18: 8.6% below the high, set on Sep 21, 2026 and 102.4% above the low. AMRX is up 56.0% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 89.7%.
Amneal Pharmaceuticals trades at 39.5x its trailing twelve-month earnings per share of $0.49. Its forward P/E of 16.2x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. The company is scheduled to report Sep/2026 results on Oct 29; analysts expect EPS of $0.21.
Summary generated from market data by MetaCap's automated system. Methodology
About Amneal Pharmaceuticals
Company profileAmneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Chirag K. Patel
- Headquarters
- Bridgewater, NJ
- Employees
- 8,700
- Website
- amneal.com
Financial highlights
Full financialsIn fiscal 2025, Amneal Pharmaceuticals generated $3.02 billion in revenue, up 8.0% from fiscal 2024, its 6th consecutive year of revenue growth. Net income was $72.1 million, for a net margin of 2.4% versus a median of -3.5% in the prior 5 years. Gross margin was 36.9% (up from 36.5%) and operating margin 13.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $3.02B | $2.79B | $2.39B | $2.21B | $2.09B |
| Growth | +8.05% | +16.73% | +8.20% | +5.67% | +5.08% |
| Net income | $72.06M | $-116.89M | $-83.99M | $-270.58M | $13.16M |
| EPS (diluted) | $0.22 | $-0.38 | $-0.48 | $-0.86 | $0.07 |
Analyst forecast
ForecastConsensus (7 analysts)
strong_buy
Avg. price target
$22.71+17.39%
- Strong buy 3
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 29, 2026
- EPS estimate
- $0.21
- Last reported (Q2 2026)
- Aug 6, 2026
- EPS actual vs est.
- $0.18 vs —
AMRX news
All AMRX newsAmneal Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ALKSAlkermes plc | 41.03 | -1.01% | $6.88B | vs AMRX |
| IONSIonis Pharmaceuticals Inc. | 44.01 | -0.34% | $7.31B | vs AMRX |
| SYRESpyre Therapeutics Inc. | 80.21 | -0.80% | $7.40B | vs AMRX |
| BLTEBelite Bio Inc ADR | 155.33 | -0.48% | $6.26B | vs AMRX |
| PRAXPraxis Precision Medicines Inc. | 266.97 | -3.97% | $7.45B | vs AMRX |
| ABVXAbivax SA ADR | 86.28 | -0.84% | $7.53B | vs AMRX |
| RYTMRhythm Pharmaceuticals Inc. | 89.13 | +0.77% | $6.14B | vs AMRX |
| KNSAKiniksa Pharmaceuticals International plc Class A | 76.75 | -1.56% | $5.99B | vs AMRX |
Indexes, lists and sector
Amneal Pharmaceuticals stock FAQ
What is Amneal Pharmaceuticals's stock price today?
AMRX last traded at $19.35 as of Oct 8, 9:59 AM EDT, down 1.55% on the day. Prices are delayed at least 15 minutes.
When is Amneal Pharmaceuticals's next earnings date?
Amneal Pharmaceuticals is expected to report earnings on Thursday, October 29, 2026. Analysts expect EPS of $0.21.
What is AMRX's P/E ratio?
AMRX trades at a trailing P/E ratio of 39.48 and a forward P/E of 16.22.
Who is Amneal Pharmaceuticals's CEO?
Mr. Chirag K. Patel is the chief executive officer of Amneal Pharmaceuticals Inc. Class A, which has about 8,700 employees.
What is the AMRX 52-week high?
The 52-week high for AMRX is $21.18 and the 52-week low is $9.56. The stock is currently 8.6% below its high.